Pheochromocytoma classification

Pheochromocytoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pheochromocytoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pheochromocytoma classification On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pheochromocytoma classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pheochromocytoma classification
CDC on Pheochromocytoma classification
Pheochromocytoma classification in the news
Blogs on Pheochromocytoma classification
Directions to Hospitals Treating Pheochromocytoma
Risk calculators and risk factors for Pheochromocytoma classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Classification

Localized (apparently benign) disease. Regional disease. Metastatic disease. The most common sites of metastasis for pheochromocytoma or extra-adrenal paraganglioma are lymph nodes, bones, lungs, and liver.